Specialty Pharmacy

A look at last week's top stories in the world of pharmacy.

Deprivation in patients with chronic obstructive pulmonary disease (COPD) is associated with increased emergency healthcare use, healthcare costs, and mortality rates, according to research.

Dupilumab (Dupixent) significantly improved disease severity in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Community Oncology Alliance survey indicates concern that Medicare Part B reforms will have a negative effect on patient care and drive up costs.

Data from two phase 3 studies showed that esketamine nasal spray demonstrated improvements in depressive symptoms for patients who did not respond to other antidepressant treatments.

Top news of the day from across the health care landscape.

COPD prevalence is increasing more rapidly in women, particularly in younger women, and COPD-related hospitalizations and deaths in women also surpass men.

At the National Community Oncology Dispensing Association's (NCODA) 2018 Spring Summit, Julianne Orr, PharmD, from Indiana University Health Simon Cancer Center, discusses the pharmacist's role in managing adherence to oral treatment regimens for patients with cancer.

Eli Lilly’s galcanezumab met its primary endpoint in a phase 3 study evaluating its use in the prevention of episodic cluster headaches.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.

The trial’s primary endpoint was a statistically significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

A new study questions medical marijuana’s role in reducing opioid use.

Top news of the day from across the health care landscape.

Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

Significant savings on biologic drugs from biosimilars may not be realized until litigation regarding patents is settled.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.

Top news of the day from across the health care landscape.

Population-based screening was found to be associated with a reduction in admissions, physician visits, and prescribed medication for individuals diagnosed with type 2 diabetes.

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

Fingolimod (Gilenya, Novartis) is the first FDA-approved treatment to treat multiple sclerosis in pediatric patients.

President Trump today called for "tougher negotiation, more competition, and much lower prices at the pharmacy counter," in a statement on lowering drug prices.

Top news of the day from across the health care landscape.

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation.

Top news of the week from Specialty Pharmacy Times.

Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

A new study examines how chemoresistance evolves over time, which could lead to improved patient outcomes and survival.

According to the case study, an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.